摘要
目的分析探讨失代偿期肝硬化采用苦参素联合胸腺肽α1治疗的抗病毒效果。方法 68例失代偿期肝硬化患者,随机分为对照组和治疗组,各34例。对照组给予基础治疗,治疗组在此基础上采用苦参素联合胸腺肽α1治疗,对比分析两组的抗病毒效果。结果治疗后,治疗组凝血酶原时间(PT)、总胆红素、血清谷丙转氨酶(ALT)、血清乙型肝炎(乙肝)病毒脱氧核糖核酸(HBV-DNA)水平改善情况明显优于对照组,差异均有统计学意义(P<0.05)。结论联合采用苦参素和胸腺肽α1治疗失代偿期肝硬化,能够有效改善患者的临床症状及各项指标,提高治疗效果,值得临床推广使用。
ObjectiveTo analyze and investigate antiviral effect of Kushenin combined with thymosin α1 in the treatment of decompensated liver cirrhosis.MethodsA total of 68 patients with decompensated liver cirrhosis were randomly divided into control group and research group, with 34 cases in each group. The control group received basic treatment, and the treatment group received additional Kushenin combined with thymosin α1 for treatment. Antiviral effects in the two groups were compared.ResultsAfter treatment, the treatment group had much better improvements of prothrombin time （PT）, total bilirubin, serum alanine aminotransferase （ALT）, and serum hepatitis B virus desoxyribonucleic acid （HBV-DNA） than the control group, and their differences all had statistical significance （P〈0.05）.ConclusionCombination of Kushenin and thymosin α1 in the treatment of decompensated liver cirrhosis can effectively improve clinical symptoms and indexes in patients. This method can improve clinical effect, and it is worthy of clinical promotion and application.
出处
《中国现代药物应用》
2015年第21期8-9,共2页
Chinese Journal of Modern Drug Application
